Bixia Tang

机构：Peking University, Beijing Institute of Genomics, Peking University Cancer Hospital, Ministry of Education

发表论文 7 篇 · 总被引 45 次 · h-index 3

代表论文

• Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report (2018 · Chinese Clinical Oncology · 被引 22)
• Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study (2025 · Med · 被引 16)
• Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial. (2021 · Journal of Clinical Oncology · 被引 4)
• Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma (2025 · Cancer Management and Research · 被引 2)
• TCR and BCR repertoire analysis reveals distinct signatures between benign and malignant ovarian tumors (2025 · Frontiers in Oncology · 被引 1)
• An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study (2023 · SSRN Electronic Journal)